• 专利标题:   Antibody-modified magnetic graphene oxide complex material used for isolating mitochondria from cell homogenates, is prepared using matrix material MagG dispersed with ferric oxide particles on graphene and covering with polydopamine shell.
  • 专利号:   CN114578042-A
  • 发明人:   LIU X, SHI X, CHANG M, XU G
  • 专利权人:   CAS DALIAN CHEM PHYSICAL INST
  • 国际专利分类:   C12N005/071, G01N033/531, G01N033/543
  • 专利详细信息:   CN114578042-A 03 Jun 2022 G01N-033/543 202273 Chinese
  • 申请详细信息:   CN114578042-A CN11383812 01 Dec 2020
  • 优先权号:   CN11383812

▎ 摘  要

NOVELTY - Antibody-modified magnetic graphene oxide complex material is prepared by taking matrix material MagG dispersed with ferric oxide particles on graphene as a core, covering outer surface of the core with a polydopamine shell and sequentially coupling the surface of shell with avidin and biotinylated antibodies. USE - The antibody-modified magnetic graphene oxide complex material is used as an immunoaffinity material for isolating mitochondria from cell homogenates (all claimed). ADVANTAGE - The complex material has controllable external magnetic field of ferric oxide, large surface area of graphene, high reactivity of polydopamine to amino group, and high specificity recognition of mitochondrial outer membrane proteins by antibodies. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following: method for preparing the antibody-modified magnetic graphene oxide complex material, involves subjecting tetroxide to solvation by solvothermal method, synthesizing the magnetic graphene oxide complex matrix material MagG by dispersing triiron particles on graphene, then depositing the polydopamine PD coating on the surface of MagG through the oxidative polymerization of dopamine to form MagG-PD, linking the avidin to the surface of MagG-PD by the addition reaction of amine-catechol to synthesize MagG-PD-avidin and coupling the biotinylated antibody TOM20 or biotinylated immunoglobulin G (IgG) to the surface of the material using the high affinity between avidin and biotin to form antibody-modified magnetic graphene oxide composites MagG-PD-avidin-TOM20 or MagG-PD-avidin-IgG; and use of the antibody-modified magnetic graphene oxide complex material as an immunoaffinity material.